Michael K. Leuchter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael K. Leuchter has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Juliana Corlier
10 shared publicationsAndrew F. Leuchter
7 shared publicationsNathaniel D. Ginder
6 shared publicationsReza Tadayonnejad
6 shared publicationsDavid E. Krantz
5 shared publicationsHewa Artin
5 shared publications
Latest Publications
- Open Access
- 22 March 2026
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 7
Signal in Noise: Characterizing changes in pupillary reactivity during repetitive transcranial magnetic stimulation (rTMS) treatment for depression
- 22 March 2026
- Published by Elsevier in Transcranial Magnetic Stimulation
- Vol. 7
Open AccessSignal in Noise: Characterizing changes in pupillary reactivity during repetitive transcranial magnetic stimulation (rTMS) treatment for depression
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21  (S5) , e098913
Broadâcoil Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimerâs Disease
Background: Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent manifestation of Alzheimerâs Disease (AD) progression. Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. We present here the rationale, design, and preliminary openâlabel data of a study using offâtheâshelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process. Methods: We are conducting a twoâstage trial of largeâcoil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimerâs Clinical Syndrome focused primarily on determining tolerability and feasibility and secondarily studying shortâterm efficacy for episodic memory. The currently active first stage involves 5â10 participants receiving openâlabel treatment for protocol refinement. The subsequent stage will consist of a 1:1 randomized, doubleâblind, sham controlled clinical trial to study feasibility and tolerability while exploring target engagement and shortâterm efficacy for memory. Participants will undergo 16 total rTMS brain stimulation sessions over the course of 5 weeks. A full openâlabel extension treatment course will be offered to the sham group after unblinding. Outcomes focus on completion rates and adverse events to demonstrate feasibility and tolerability. Further exploratory outcomes will include neuropsychological assessments, electroencephalography (EEG), neuroimaging, and blood biomarkers to demonstrate feasibility of collection and explore preliminary changes in these measures. Results: We anticipate this treatment is feasible and tolerable and may show evidence of target engagement and clinical improvement. We plan to present current preliminary openâlabel data as analyzed at AAIC. Conclusion: Should we achieve expected positive outcomes in feasibility and tolerability, this will justify future work focusing on clear demonstrations of clinical efficacy and biomarker engagement, as well as enhancement of generalizability and scalability. Trial Registration: Clinicaltrials.gov NCT06597942
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21  (S5) , e098913
Open AccessBroadâcoil Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimerâs Disease
Background: Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent manifestation of Alzheimerâs Disease (AD) progression. Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. We present here the rationale, design, and preliminary openâlabel data of a study using offâtheâshelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process. Methods: We are conducting a twoâstage trial of largeâcoil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimerâs Clinical Syndrome focused primarily on determining tolerability and feasibility and secondarily studying shortâterm efficacy for episodic memory. The currently active first stage involves 5â10 participants receiving openâlabel treatment for protocol refinement. The subsequent stage will consist of a 1:1 randomized, doubleâblind, sham controlled clinical trial to study feasibility and tolerability while exploring target engagement and shortâterm efficacy for memory. Participants will undergo 16 total rTMS brain stimulation sessions over the course of 5 weeks. A full openâlabel extension treatment course will be offered to the sham group after unblinding. Outcomes focus on completion rates and adverse events to demonstrate feasibility and tolerability. Further exploratory outcomes will include neuropsychological assessments, electroencephalography (EEG), neuroimaging, and blood biomarkers to demonstrate feasibility of collection and explore preliminary changes in these measures. Results: We anticipate this treatment is feasible and tolerable and may show evidence of target engagement and clinical improvement. We plan to present current preliminary openâlabel data as analyzed at AAIC. Conclusion: Should we achieve expected positive outcomes in feasibility and tolerability, this will justify future work focusing on clear demonstrations of clinical efficacy and biomarker engagement, as well as enhancement of generalizability and scalability. Trial Registration: Clinicaltrials.gov NCT06597942
- Open Access
- 19 August 2025
- Published by Springer Nature in Research Square
Efficacy of 5x5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression
Accelerated repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD), with an FDA-cleared protocol utilizing 10 sessions of prolonged intermittent Theta Burst Stimulation (piTBS) per day for five days. However, it remains unclear how many sessions and pulses are necessary to achieve benefit. We examined efficacy of five stimulation sessions per day for five days (â5x5â) of either piTBS or individualized, electroencephalogram-based âresonant frequencyâ (RF) stimulation. We compared MDD symptom improvement (PHQ-9) between two groups: 1) accelerated patients (N = 40) undergoing 5x5 treatment (patients received piTBS or RF rTMS) and 2) conventional patients (N = 135) receiving standard once daily rTMS. Both protocols ameliorated MDD symptoms and there were no statistically significant differences in depression symptom changes (p = .07) between the accelerated 5x5 protocol (mean PHQ-9: pre-rTMS = 17.68, post-rTMS = 10.98) and conventional once-daily treatment (mean PHQ-9: pre-rTMS = 17.83, post-rTMS = 8.97). There was no significant difference in improvement between the piTBS and RF 5x5 protocols (p = 0.9). A PHQ-9 median split of 5x5 patients revealed that the top half of patients showed robust depression improvement (69%) while the bottom half received no significant benefit (8%) by day 5. However, the bottom half showed significant improvement (36%) at two-to-four-week follow up (p = 0.001). These results suggest 5x5 accelerated rTMS treatment is as effective as once daily rTMS treatment and that the efficacy of accelerated treatment may not be accurately assessed until weeks after treatment completion.
- 19 August 2025
- Published by Springer Nature in Research Square
Open AccessEfficacy of 5x5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression
Accelerated repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD), with an FDA-cleared protocol utilizing 10 sessions of prolonged intermittent Theta Burst Stimulation (piTBS) per day for five days. However, it remains unclear how many sessions and pulses are necessary to achieve benefit. We examined efficacy of five stimulation sessions per day for five days (â5x5â) of either piTBS or individualized, electroencephalogram-based âresonant frequencyâ (RF) stimulation. We compared MDD symptom improvement (PHQ-9) between two groups: 1) accelerated patients (N = 40) undergoing 5x5 treatment (patients received piTBS or RF rTMS) and 2) conventional patients (N = 135) receiving standard once daily rTMS. Both protocols ameliorated MDD symptoms and there were no statistically significant differences in depression symptom changes (p = .07) between the accelerated 5x5 protocol (mean PHQ-9: pre-rTMS = 17.68, post-rTMS = 10.98) and conventional once-daily treatment (mean PHQ-9: pre-rTMS = 17.83, post-rTMS = 8.97). There was no significant difference in improvement between the piTBS and RF 5x5 protocols (p = 0.9). A PHQ-9 median split of 5x5 patients revealed that the top half of patients showed robust depression improvement (69%) while the bottom half received no significant benefit (8%) by day 5. However, the bottom half showed significant improvement (36%) at two-to-four-week follow up (p = 0.001). These results suggest 5x5 accelerated rTMS treatment is as effective as once daily rTMS treatment and that the efficacy of accelerated treatment may not be accurately assessed until weeks after treatment completion.
- Open Access
- 1 January 2025
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 11  (1)
Broad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design
INTRODUCTION: Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent contributor to the clinical progression of Alzheimer's disease (AD). Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. Here, we present the rationale and design of a study using offâtheâshelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process. METHODS: We will conduct a twoâstage trial of largeâcoil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimer's Clinical Syndrome focused primarily on determining tolerability and feasibility and secondarily focused on determining shortâterm efficacy for memory. The first stage will involve 5 to 10 participants receiving openâlabel active treatment to refine the protocol. The following second stage will consist of a 1:1 randomized, doubleâblind, shamâcontrolled clinical trial to study feasibility and tolerability while exploring target engagement and shortâterm efficacy for memory. Participants will undergo 16 total rTMS brain stimulation sessions over the course of 5 weeks. A full course of openâlabel active treatment will be offered as an extension to the sham group after unblinding. Outcomes will focus on completion rates and adverse events to demonstrate feasibility and tolerability. Further exploratory outcomes will include neuropsychological assessments, electroencephalography, neuroimaging, and blood biomarkers to demonstrate the feasibility of collection and explore preliminary changes in these measures. RESULTS: We anticipate this treatment is feasible and tolerable and may show evidence of target engagement and clinical improvement. DISCUSSION: Should we achieve expected positive outcomes in feasibility and tolerability, this will justify future work focusing on clear demonstrations of clinical efficacy and biomarker engagement, as well as enhancement of generalizability and scalability. Highlights: Inductionâtoâmaintenance repetitive transcranial magnetic stimulation (rTMS) of the precuneus is a promising treatment for Alzheimer's disease (AD), though recent methods require intensive personalization. We propose here a trial design of precuneus rTMS in mildâtoâearlyâmoderate AD dementia using exclusively offâtheâshelf equipment and protocol modifications to reduce participant burden. Our two novel modifications from prior work are (1) using a larger rTMS coil, and (2) consolidating the induction phase of treatment. This trial focuses primarily on tolerability and feasibility while exploring clinical measures of efficacy and biomarkers of target engagement. Our trial is registered at ClinicalTrials.gov NCT06597942.
- 1 January 2025
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 11  (1)
Open AccessBroad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design
INTRODUCTION: Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent contributor to the clinical progression of Alzheimer's disease (AD). Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. Here, we present the rationale and design of a study using offâtheâshelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process. METHODS: We will conduct a twoâstage trial of largeâcoil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimer's Clinical Syndrome focused primarily on determining tolerability and feasibility and secondarily focused on determining shortâterm efficacy for memory. The first stage will involve 5 to 10 participants receiving openâlabel active treatment to refine the protocol. The following second stage will consist of a 1:1 randomized, doubleâblind, shamâcontrolled clinical trial to study feasibility and tolerability while exploring target engagement and shortâterm efficacy for memory. Participants will undergo 16 total rTMS brain stimulation sessions over the course of 5 weeks. A full course of openâlabel active treatment will be offered as an extension to the sham group after unblinding. Outcomes will focus on completion rates and adverse events to demonstrate feasibility and tolerability. Further exploratory outcomes will include neuropsychological assessments, electroencephalography, neuroimaging, and blood biomarkers to demonstrate the feasibility of collection and explore preliminary changes in these measures. RESULTS: We anticipate this treatment is feasible and tolerable and may show evidence of target engagement and clinical improvement. DISCUSSION: Should we achieve expected positive outcomes in feasibility and tolerability, this will justify future work focusing on clear demonstrations of clinical efficacy and biomarker engagement, as well as enhancement of generalizability and scalability. Highlights: Inductionâtoâmaintenance repetitive transcranial magnetic stimulation (rTMS) of the precuneus is a promising treatment for Alzheimer's disease (AD), though recent methods require intensive personalization. We propose here a trial design of precuneus rTMS in mildâtoâearlyâmoderate AD dementia using exclusively offâtheâshelf equipment and protocol modifications to reduce participant burden. Our two novel modifications from prior work are (1) using a larger rTMS coil, and (2) consolidating the induction phase of treatment. This trial focuses primarily on tolerability and feasibility while exploring clinical measures of efficacy and biomarkers of target engagement. Our trial is registered at ClinicalTrials.gov NCT06597942.
- 21 September 2024
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 179, 295-299
Safety and efficacy of targeting the supplementary motor area with double-cone deep transcranial magnetic stimulation vs figure-eight coil in treatment of obsessive-compulsive disorder with comorbid major depressive disorder
- 21 September 2024
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 179, 295-299
Safety and efficacy of targeting the supplementary motor area with double-cone deep transcranial magnetic stimulation vs figure-eight coil in treatment of obsessive-compulsive disorder with comorbid major depressive disorder
- Open Access
- 25 March 2024
- Published by Elsevier in International Psychogeriatrics
- Vol. 36  (11) , 1070-1075
The effect of older age on outcomes of rTMS treatment for treatment-resistant depression
- 25 March 2024
- Published by Elsevier in International Psychogeriatrics
- Vol. 36  (11) , 1070-1075
Open AccessThe effect of older age on outcomes of rTMS treatment for treatment-resistant depression
- 21 February 2024
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 27  (4) , 774-780
Sequential Multilocus Repetitive Transcranial Magnetic Stimulation for Treatment of Tinnitus With and Without Comorbid Major Depressive Disorder
- 21 February 2024
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 27  (4) , 774-780
Sequential Multilocus Repetitive Transcranial Magnetic Stimulation for Treatment of Tinnitus With and Without Comorbid Major Depressive Disorder
- 14 November 2023
- Published by Elsevier in Psychiatry Research
- Vol. 330, 115608
A comparison of self- and observer-rated scales for detecting clinical improvement during repetitive transcranial stimulation (rTMS) treatment of depression
- 14 November 2023
- Published by Elsevier in Psychiatry Research
- Vol. 330, 115608
A comparison of self- and observer-rated scales for detecting clinical improvement during repetitive transcranial stimulation (rTMS) treatment of depression
- Open Access
- 18 October 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16  (6) , 1566-1571
Pretreatment pupillary reactivity is associated with differential early response to 10 Hz and intermittent theta-burst repetitive transcranial magnetic stimulation (rTMS) treatment of major depressive disorder (MDD)
- 18 October 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16  (6) , 1566-1571
Open AccessPretreatment pupillary reactivity is associated with differential early response to 10 Hz and intermittent theta-burst repetitive transcranial magnetic stimulation (rTMS) treatment of major depressive disorder (MDD)